Sejong General Hospital   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Incheon Korea, Republic of (1982)

Organization Overview

First Clinical Trial
2011
NCT01813799
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Mediplex Sejong Hospital | Sejong General Hospital | Sejong Hospital

Active Ingredients

Drugs in Phase 4 Trials (1)

acetylsalicylic acid (aspirin) (1 trial)

Drugs in Phase 3 Trials (4)

carvedilol (coreg) (1 trial)

ckd-825 (1 trial)

fimasartan (kanarb) (1 trial)

valsartan (diovan) (1 trial)

Drugs in Phase 2 Trials (1)

da-9801 (1 trial)

Drugs in Other Trials (2)

adenosine (Adenocard) (1 trial)

nicorandil (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrial Fibrillation (Phase 3)

Coronary Artery Disease (Phase 4)

Diabetic Neuropathies (Phase 2)

Essential Hypertension (Phase 3)

Hypertension (Phase 3)

Neuralgia (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 6
  • # of Trial APIs: 8